Boardroom Alpha
Boardroom Alpha
CYRX · Current Report (Form 8-K) · Filed June 9, 2026

Cryoport Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 9, 2026
Period
Jun 5, 2026
Ticker
CYRX
Accession
0001104659-26-071892
Boardroom Alpha · Filing insights

Six directors elected; Deloitte ratified; executive compensation approved; equity plan amended to increase authorized shares.

About Cryoport Inc
Market cap
$815M
1Y TSR
+87.3%
3Y TSR
+3.9%
Board grade
C-
Sector
Industrials
CEO
Jerrell Shelton
Last annual meeting: Jun 5, 2026 · View full Cryoport Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

  

FORM 8-K

 

CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2026

 

CRYOPORT, INC. 

(Exact name of registrant as specified in its charter)

 

Nevada   001-34632   88-0313393
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)
         

112 Westwood Place, Suite 350

Brentwood, TN 37027
(Address of principal executive offices, including zip code)
         
Registrant’s telephone number, including area code: (949) 470-2300
 
Not Applicable
(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.001 par value   CYRX   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On June 5, 2026, Cryoport, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of stockholders at the Annual Meeting, each of which is described in detail in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026 (“Proxy Statement”), are set forth below.

 

Proposal No. 1: Election of Directors. The individuals listed below were elected to serve as directors of the Company until the Company’s 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or their earlier death, resignation, or removal:

 

Director Nominee

Votes For

Votes Withheld

Broker Non-Votes

Linda Baddour 38,883,910 3,835,861 4,507,992
Daniel M. Hancock 40,948,468 1,771,303 4,507,992
Robert Hariri, M.D., Ph.D. 40,675,339 2,044,432 4,507,992
Ram M. Jagannath 40,739,957 1,979,814 4,507,992
Ramkumar Mandalam, Ph.D. 40,356,471 2,363,300 4,507,992
Jerrell W. Shelton 40,937,536 1,782,235 4,507,992

 

Proposal No. 2: Ratification of the appointment of Deloitte and Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2026. This proposal was approved as set forth below:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

47,014,962 21,499 191,302

 

Proposal No. 3: Advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. This proposal was approved as set forth below:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

39,533,693 2,390,915 795,163 4,507,992

 

Proposal No. 4: Amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to, among other things, increase the number of authorized shares under the plan. This proposal was approved as set forth below:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

30,110,893 12,591,758 17,120 4,507,992

 

Item 9.01.Financial Statements and Exhibits.

 

 (d)           Exhibits.  

 

Exhibit No.   Description
10.1   Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended, effective June 5, 2026)
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 9, 2026 Cryoport Inc.
   
  /s/ Robert Stefanovich
  Robert Stefanovich
  Chief Financial Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cryoport Inc (CYRX)

Reference

Frequently asked questions

When did Cryoport Inc file this 8-K?
Cryoport Inc (CYRX) filed this Current Report (Form 8-K) with the SEC on June 9, 2026. The accession number assigned by EDGAR is 0001104659-26-071892.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Six directors elected; Deloitte ratified; executive compensation approved; equity plan amended to increase authorized shares. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Cryoport Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Cryoport Inc has filed under CIK 1124524, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer